{"id":"zilucoplan-ra101495","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Injection site reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by binding to sphingosine 1-phosphate receptor 1 (S1P1), which is involved in the regulation of immune cell trafficking and activation. By modulating this receptor, zilucoplan aims to reduce inflammation and autoimmune responses.","oneSentence":"Zilucoplan is a sphingosine 1-phosphate receptor modulator.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:41:25.234Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsing forms of multiple sclerosis"}]},"trialDetails":[{"nctId":"NCT06471361","phase":"PHASE3","title":"A Study to Evaluate the Safe and Effective Use of a Zilucoplan Auto-injector by Study Participants With Generalized Myasthenia Gravis","status":"COMPLETED","sponsor":"UCB Biopharma SRL","startDate":"2024-08-27","conditions":"Generalized Myasthenia Gravis","enrollment":31},{"nctId":"NCT06435312","phase":"PHASE3","title":"An Open-label Extension Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis","status":"ENROLLING_BY_INVITATION","sponsor":"UCB Biopharma SRL","startDate":"2024-11-19","conditions":"Generalized Myasthenia Gravis","enrollment":8},{"nctId":"NCT06055959","phase":"PHASE2, PHASE3","title":"A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis","status":"RECRUITING","sponsor":"UCB Biopharma SRL","startDate":"2024-10-16","conditions":"Generalized Myasthenia Gravis","enrollment":8},{"nctId":"NCT06961747","phase":"PHASE1","title":"A Study to Assess Zilucoplan Concentration in Breast Milk of Healthy Lactating Women","status":"RECRUITING","sponsor":"UCB Biopharma SRL","startDate":"2025-07-09","conditions":"Healthy Participants","enrollment":15},{"nctId":"NCT04225871","phase":"PHASE3","title":"Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis","status":"ACTIVE_NOT_RECRUITING","sponsor":"UCB Biopharma SRL","startDate":"2019-12-23","conditions":"Generalized Myasthenia Gravis","enrollment":200},{"nctId":"NCT06511076","phase":"PHASE1","title":"A Study to Evaluate Zilucoplan Injected Subcutaneously Either by a Prefilled Syringe or an Auto-injector in Healthy Adult Participants","status":"COMPLETED","sponsor":"UCB Biopharma SRL","startDate":"2024-08-05","conditions":"Healthy Volunteers","enrollment":14},{"nctId":"NCT05514873","phase":"PHASE3","title":"An Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Zilucoplan in Participants With Generalized Myasthenia Gravis Who Were Previously Receiving Intravenous Complement Component 5 Inhibitors","status":"COMPLETED","sponsor":"UCB Biopharma SRL","startDate":"2022-10-31","conditions":"Generalized Myasthenia Gravis","enrollment":26},{"nctId":"NCT04115293","phase":"PHASE3","title":"Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis","status":"COMPLETED","sponsor":"Ra Pharmaceuticals, Inc.","startDate":"2019-09-17","conditions":"Myasthenia Gravis, Generalized","enrollment":174},{"nctId":"NCT03225287","phase":"PHASE2","title":"Extension Study of RA101495 for Patients With PNH Who Have Completed a Zilucoplan (RA101495) Clinical Study","status":"TERMINATED","sponsor":"Ra Pharmaceuticals, Inc.","startDate":"2017-07-17","conditions":"Paroxysmal Nocturnal Hemoglobinuria (PNH)","enrollment":19},{"nctId":"NCT03078582","phase":"PHASE2","title":"Phase 2 Safety and Efficacy Study of Zilucoplan (RA101495) to Treat PNH Patients","status":"COMPLETED","sponsor":"Ra Pharmaceuticals","startDate":"2017-03-08","conditions":"Paroxysmal Nocturnal Hemoglobinuria (PNH)","enrollment":26},{"nctId":"NCT03030183","phase":"PHASE2","title":"Phase 2 Safety and Efficacy Study of Zilucoplan (RA101495) to Treat PNH Patients Who Have an Inadequate Response to Eculizumab","status":"COMPLETED","sponsor":"Ra Pharmaceuticals","startDate":"2017-04-17","conditions":"Paroxysmal Nocturnal Hemoglobinuria (PNH)","enrollment":3},{"nctId":"NCT03315130","phase":"PHASE2","title":"Safety and Efficacy Study of RA101495 in Subjects With Generalized Myasthenia Gravis","status":"COMPLETED","sponsor":"Ra Pharmaceuticals","startDate":"2017-10-11","conditions":"Generalized Myasthenia Gravis","enrollment":45}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"zilucoplan (RA101495)","genericName":"zilucoplan (RA101495)","companyName":"UCB Biopharma SRL","companyId":"ucb-biopharma-srl","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Zilucoplan is a sphingosine 1-phosphate receptor modulator. Used for Relapsing forms of multiple sclerosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}